Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
EDITORIAL
The role of liquid biopsy in early diagnosis of Lung Cancer in patients with Pulmonary Fibrosis
1
First Academic Department of Pneumonology, Interstitial Lung Diseases Unit, Hospital for Diseases of the Chest, “Sotiria”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Corresponding author
Argyrios Tzouvelekis
First Academic Department of Pneumonology Hospital for Diseases of the Chest, “Sotiria” 152 Messogion Avenue, 11527, Athens, Greece
First Academic Department of Pneumonology Hospital for Diseases of the Chest, “Sotiria” 152 Messogion Avenue, 11527, Athens, Greece
Pneumon 2017;30(4):221-223
KEYWORDS
REFERENCES (34)
1.
Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. European respiratory review: an official journal of the European Respiratory Society 2015; 24:102-14.
2.
Raghu G, Collard HR, Egan JJ, et al. Fibrosis AEJACoIP. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
3.
Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/ JRS/ALAT Clinical Practice Guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192:e3-19.
4.
Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move. Lancet Respir Med 2014; 2:17-9.
5.
Tzilas V, Bouros E, Tzouvelekis A, Bouros D. Guidelines for Idiopathic Pulmonary Fibrosis: Everything Flows. Respiration 2017; 93:401-3.
6.
Tzilas V, Valeyre D, Tzouvelekis A, Bouros D. Taking a giant step in the diagnosis of idiopathic pulmonary fibrosis. Lancet Respir Med 2017; S2213-2600(17)30443-5.
7.
Tzouvelekis A, Tzilas V, Papiris S, Aidinis V, Bouros D. Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: A patient’s “Q and A” approach. Pulm Pharmacol Ther 2017; 42:21-4.
8.
Tzouvelekis A, Yu G, Lino Cardenas CL, et al. SH2 Domaincontaining phosphatase-2 is a novel antifibrotic regulator in pulmonary fibrosis. Am J Respir Crit Care Med 2017; 195:500-14.
9.
Antoniou KM, Tzouvelekis A, Alexandrakis MG, et al. Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J Interferon Cytokine Res 2006; 26:400-5.
10.
Bouros D, Antoniou KM, Tzouvelekis A, Siafakas NM. Interferongamma 1b for the treatment of idiopathic pulmonary fibrosis. Expert Opin Biol Ther 2006; 6:1051-60.
11.
Spagnolo P, Sverzellati N, Rossi G, et al. Idiopathic pulmonary fibrosis: an update. Ann Med 2015; 47:15-27.
12.
Tzouvelekis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 2015; 11:359-70.
13.
Richeldi L, du Bois RM, Raghu G, et al, Investigators IT. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071-82.
14.
King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-92.
15.
Tzouvelekis A, Karampitsakos T, Kontou M, et al. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study. Pulm Pharmacol Ther 2018; S1094-5539(17)30243-2.
16.
Tzouvelekis A, Karampitsakos T, Ntolios P, et al. Longitudinal “Real-World” outcomes of pirfenidone in idiopathic pulmonary fibrosis in Greece. Front Med (Lausanne) 2017; 4: 213.
17.
Tzouvelekis A, Bouros E, Tzilas V, Bouros D. Pirfenidone in Idiopathic Pulmonary Fibrosis “RECAP-itulating Safety into the Real World”. Respiration 2017; 94:405-7.
18.
Tzouvelekis A, Ntolios P, Karampitsakos T, et al. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study. Pulm Pharmacol Ther 2017; 46:48-53.
19.
Papaioannou O, Karampitsakos T, Barbayianni I, et al. Metabolic disorders in chronic lung diseases. Frontiers in Medicine 2018; 4.
20.
Karampitsakos T, Tzilas V, Tringidou R, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2017; 45:1-10.
21.
Thannickal VJ. Mechanistic links between aging and lung fibrosis. Biogerontology 2013; 14:609-15.
22.
Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009; 14:723-8.
23.
Guyard A, Danel C, Theou-Anton N, et al. Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. Respir Res 2017; 18:120.
24.
Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 2013; 22:265-72.
25.
Heitzer E, Perakis S, Geigl JB, Speicher MR. The potential of liquid biopsies for the early detection of cancer. NPJ Precision Oncology 2017; 1:36.
26.
Ryerson CJ, Cottin V, Brown KK, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J 2015; 46:512-20.
27.
Tzouvelekis A, Spagnolo P, Bonella F, et al. Patients with IPF and lung cancer: diagnosis and management. Lancet Respir Med 2017; S2213-2600(17)30478-2.
28.
Wielscher M, Vierlinger K, Kegler U, Ziesche R, Gsur A, Weinhäusel A. Diagnostic performance of plasma DNA methylation profiles in lung cancer, pulmonary fibrosis and COPD. EBioMedicine 2015; 2:929-36.
29.
Ryu C, Sun H, Gulati M, et al. Extracellular mitochondrial DNA is generated by fibroblasts and predicts death in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017; 196:1571- 81.
30.
Herazo-Maya JD, Sun J, Molyneaux PL, et al. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respir Med 2017; 5:857-68.
31.
Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med 2017; 5:946-55.
32.
Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr Opin Pulm Med 2015; 21:470-8.
33.
Tzouvelekis A, Herazo-Maya J, Sakamoto K, Bouros D. Biomarkers in the evaluation and management of idiopathic pulmonary fibrosis. Curr Top Med Chem 2016; 16:1587-98.
34.
Tzouvelekis A, Kouliatsis G, Anevlavis S, Bouros D. Serum biomarkers in interstitial lung diseases. Respiratory Research 2005; 6:(Article number 78):24.
Share
RELATED ARTICLE
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
